SynthesisJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2023
Yinyanghuo () and its components for chronic obstructive pulmonary disease: preclinical evidence and possible mechanisms.
Synthesis in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo integrate Meta-analysis and bioinformatics strategies in the preliminary exploration of the potential mechanism of Yinyanghuo () and its extract in treating chronic obstructive pulmonary disease (COPD).
methodsFirst, Meta-analysis was carried out. The Chinese and English literature of Yinyanghuo () in treating COPD was searched using the systematic strategy of combining subject words with free words. The included studies were evaluated by the SYRCLE risk bias assessment tool, after which the review manager software was used to combine the effect quantities for statistical analysis. Then, based on bioinformatics technology, the active ingredients and their targets of Yinyanghuo () were screened, and the intersection genes were obtained by mapping and comparing with the targets of COPD. The "medicinal materials-compounds-targets model" was constructed, and the key pathways were annotated. Finally, the core target was docked with important compounds.
resultsA total of 8 studies were included in the Meta-analysis. The results showed that the Yinyanghuo (Herba Epimedii Brevicornus) group could significantly down-regulate pro-inflammatory factors such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-8 and increase the expression of anti-inflammatory factors and antioxidant factors such as IL-10 and phospho-protein kinase B (p-AKT) in the COPD model (all P < 0.05). A total of 23 active components and 102 corresponding target genes of Yinyanghuo (Herba Epimedii Brevicornus) were obtained by bioinformatics technology, among which 17 compounds and 63 targets were closely related to COPD. The results of enrichment analysis mainly included TNF signaling pathway, phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, cancer signaling pathway, and other inflammatory reactions, oxidative stress, and tumor-related pathways. The molecular docking results showed that the binding energy fractions of the top five components of 24-epicampesterol with 10 core targets such as IL-6 were all less than ﹣5.0 kcal/mol, suggesting good binding ability.
conclusionsMeta-analysis and bioinformatics results indicated that the therapeutic effect of Yinyanghuo () and its components on COPD might be related to antagonizing inflammation and oxidative stress. The above findings provide a preliminary basis for the development of Yinyanghuo () as a natural drug for preventing and treating COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.